Blood · 2012 · 208 citations · 21 references
Life SciencesImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentCytokines In Tumor ImmunityMacrophage BiologyTumor Microenvironment ModulationTumor-associated MacrophagesTumor-infiltrating LymphocytesCancer-associated Macrophage SignalingCancer-associated MacrophagesHodgkin Lymphoma TherapyHodgkin Lymphoma TreatmentMacrophage BiomarkersMacrophage DysfunctionTumor-associated CytokinesTumor-associated Macrophage Recruitment
Increased tumor-associated macrophages (TAMs) are reported to be associated with poor prognosis in classic Hodgkin lymphoma (CHL). We investigated the prognostic significance of TAMs in the E2496 Intergroup trial, a multicenter phase 3 randomized controlled trial comparing ABVD and Stanford V chemotherapy in locally extensive and advanced stage CHL. Tissue microarrays were constructed from formalin-fixed, paraffin-embedded tumor tissue and included 287 patients. Patients were randomly assigned into training (n = 143) and validation (n = 144) cohorts. Immunohistochemistry for CD68 and CD163, and in situ hybridization for EBV-encoded RNA were performed. CD68 and CD163 IHC were analyzed by computer image analysis; optimum thresholds for overall survival (OS) were determined in the training cohort and tested in the independent validation cohort. Increased CD68 and CD163 expression was significantly associated with inferior failure-free survival and OS in the validation cohort. Increased CD68 and CD163 expression was associated with increased age, EBV-encoded RNA positivity, and mixed cellularity subtype of CHL. Multivariate analysis in the validation cohort showed increased CD68 or CD163 expression to be significant independent predictors of inferior failure-free survival and OS. We demonstrate the prognostic significance of TAMs in locally extensive and advanced-stage CHL in a multicenter phase 3 randomized controlled clinical trial.
21
Robert L. Camp, Marisa Dolled‐Filhart, David L. Rimm · Clinical Cancer Research · 2004 · 3.9K citations
Medicine, Biostatistics, Oncology +17
A Prognostic Score for Advanced Hodgkin's Disease
Dirk Hasenclever, Volker Diehl, Jamés O. Armitage et al. · New England Journal of Medicine · 1998 · 1.7K citations · Full text
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Christian Steidl, Tang Lee, Sohrab P. Shah et al. · New England Journal of Medicine · 2010 · 1.3K citations · Full text
Sean K. Lau, Peiguo Chu, Lawrence M. Weiss · American Journal of Clinical Pathology · 2004 · 338 citations